跳至主要内容
临床试验/JPRN-UMIN000003653
JPRN-UMIN000003653已完成2 期

Phase II study of S-1 plus amrubicin as the 2nd-line treatment for non-small cell lung cancer without EGFR mutation - Phase II study of S-1 plus amrubicin as the 2nd-line treatment for non-small cell lung cancer without EGFR mutation

Kanagawa Cancer Center0 个研究点目标入组 20 人开始时间: 2010年5月25日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)patients previously treated with amrubicin and 5-FU derivative drugs 2)pleural effusion(eligible for difficult puncture case or cytologically negative and clinically ignorable case) 3)evident pericardial effusion 4)serious complications below uncontrollable angina pectoris, myocardial infarction within 3 months or heart failure uncontrollable diabetes uncontrollable hypertension severe infection 5)pulmonary fibrosis or interstitial pneumonitis evident 6)HB and HC virus carrier 7)now pregnant or lactation 8)difficult to perform or continue of this study

研究者

相似试验